SI2358717T1 - Aminotetrahidropirani kot dipeptidil peptidazni-iv inhibitorji za zdravljenje ali prepreäśevanje sladkorne bolezni - Google Patents

Aminotetrahidropirani kot dipeptidil peptidazni-iv inhibitorji za zdravljenje ali prepreäśevanje sladkorne bolezni

Info

Publication number: SI2358717T1
Authority: SI; Slovenia
Prior art keywords: aminotetrahydropyrans; diabetes; inhibitors; prevention; treatment
Prior art date: 2008-11-13

Application number

SI200930757T

Other languages

English (en)

Inventor

Tesfaye Biftu

Ping Chen

Jason M. Cox

Ann E. Weber

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-13

Filing date

2009-11-11

Publication date

2014-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41559521&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2358717(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-11 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2014-02-28 Publication of SI2358717T1 publication Critical patent/SI2358717T1/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

SI200930757T 2008-11-13 2009-11-11 Aminotetrahidropirani kot dipeptidil peptidazni-iv inhibitorji za zdravljenje ali prepreäśevanje sladkorne bolezni SI2358717T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19917908P	2008-11-13	2008-11-13
PCT/US2009/063976 WO2010056708A1 (en)	2008-11-13	2009-11-11	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP20090756204 EP2358717B1 (en)	2008-11-13	2009-11-11	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Publications (1)

Publication Number	Publication Date
SI2358717T1 true SI2358717T1 (sl)	2014-02-28

Family

ID=41559521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200930757T SI2358717T1 (sl)	2008-11-13	2009-11-11	Aminotetrahidropirani kot dipeptidil peptidazni-iv inhibitorji za zdravljenje ali prepreäśevanje sladkorne bolezni

Country Status (40)

Country	Link
US (8)	US8143289B2 (sl)
EP (4)	EP2676959A1 (sl)
JP (2)	JP4854825B1 (sl)
KR (2)	KR101454093B1 (sl)
CN (1)	CN102272136B (sl)
AR (1)	AR074306A1 (sl)
AU (1)	AU2009314191B2 (sl)
BR (1)	BRPI0921375B8 (sl)
CA (1)	CA2742783C (sl)
CL (1)	CL2011001082A1 (sl)
CO (1)	CO6382129A2 (sl)
CR (1)	CR20110257A (sl)
CY (1)	CY1114617T1 (sl)
DK (1)	DK2358717T3 (sl)
DO (1)	DOP2011000128A (sl)
EA (1)	EA018613B1 (sl)
EC (1)	ECSP11011044A (sl)
ES (1)	ES2432191T3 (sl)
GE (1)	GEP20135724B (sl)
HK (1)	HK1154849A1 (sl)
HN (1)	HN2011001256A (sl)
HR (1)	HRP20130924T1 (sl)
IL (2)	IL212485A (sl)
JO (1)	JO2870B1 (sl)
MA (1)	MA32887B1 (sl)
MX (1)	MX2011005044A (sl)
MY (1)	MY150787A (sl)
NI (1)	NI201100081A (sl)
NZ (1)	NZ592826A (sl)
PA (1)	PA8848201A1 (sl)
PE (1)	PE20120027A1 (sl)
PL (1)	PL2358717T3 (sl)
PT (1)	PT2358717E (sl)
RS (1)	RS52946B (sl)
SI (1)	SI2358717T1 (sl)
SV (1)	SV2011003903A (sl)
TN (1)	TN2011000201A1 (sl)
TW (1)	TWI398443B (sl)
UA (1)	UA101414C2 (sl)
WO (1)	WO2010056708A1 (sl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0915720A2 (pt)	2008-06-12	2015-08-04	Janssen Pharmaceutica Nv	Moduladores de diaminopiridina, pirimidina, e piridazina do receptor de histamina h4
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
BR112012004335A8 (pt) *	2009-09-02	2016-06-21	Merck Sharp & Dohme	Composto, composição farmacêutica, e, uso do composto.
US8716482B2 (en)	2009-09-25	2014-05-06	Merck Sharp & Dohme Corp.	Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP2538783B1 (en)	2010-02-22	2016-06-01	Merck Sharp & Dohme Corp.	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8980929B2 (en)	2010-05-21	2015-03-17	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2648517B1 (en)	2010-12-06	2015-08-05	Merck Sharp & Dohme Corp.	Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2714069A4 (en) *	2011-05-25	2015-06-24	Amylin Pharmaceuticals Llc	LONG-TERM CONJUGATES WITH TWO HORMONES
CN103702562A (zh) *	2011-06-29	2014-04-02	默沙东公司	用于制备手性二肽基肽酶-iv抑制剂的方法
WO2013006526A2 (en)	2011-07-05	2013-01-10	Merck Sharp & Dohme Corp.	Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2814485A4 (en)	2012-02-17	2015-08-26	Merck Sharp & Dohme	DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP2874622A4 (en)	2012-07-23	2015-12-30	Merck Sharp & Dohme	TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
EP2874626A4 (en) *	2012-07-23	2016-03-23	Merck Sharp & Dohme	TREATMENT OF DIABETES BY ADMINISTRATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITORS
TWI500613B (zh)	2012-10-17	2015-09-21	Cadila Healthcare Ltd	新穎之雜環化合物
EP3038465B1 (en) *	2013-08-30	2021-10-06	Merck Sharp & Dohme Corp.	Oral pharmaceutical formulation of omarigliptin
JP6329631B2 (ja) *	2014-03-20	2018-05-23	エッフェ・イ・エッセ − ファッブリカ・イタリアーナ・シンテテイチ・ソチエタ・ペル・アツィオーニＦ．Ｉ．Ｓ． − ＦａｂｂｒｉｃａＩｔａｌｉａｎａＳｉｎｔｅｔｉｃｉＳ．ｐ．Ａ．	オマリグリプチンの重要な中間体の製造方法
CN105037367A (zh) *	2014-04-18	2015-11-11	四川海思科制药有限公司	氨基六元环类衍生物及其在医药上的应用
CN105085528A (zh) *	2014-05-15	2015-11-25	成都贝斯凯瑞生物科技有限公司	作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
CN105085530B (zh) *	2014-05-23	2019-01-04	四川海思科制药有限公司	三元稠合环取代的氨基六元环类衍生物及其在医药上的应用
JP6535034B2 (ja) *	2014-06-17	2019-06-26	スーチュアンハイスークファーマシューティカルカンパニーリミテッド	アミノピラン環誘導体及びその組成物と用途
CN105294694B (zh) *	2014-06-18	2019-01-04	四川海思科制药有限公司	氨基六元环类衍生物及其在医药上的应用
JP6574474B2 (ja)	2014-07-21	2019-09-11	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法
CN105985357A (zh) *	2015-02-12	2016-10-05	北京赛林泰医药技术有限公司	取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
CN106478631B (zh) *	2015-08-24	2019-04-05	四川科伦药物研究院有限公司	长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法
WO2017031918A1 (zh) *	2015-08-24	2017-03-02	四川科伦药物研究院有限公司	长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法
WO2017032705A1 (en)	2015-08-25	2017-03-02	Sandoz Ag	Crystalline form of omarigliptin
TWI681962B (zh) *	2015-08-26	2020-01-11	大陸商四川海思科製藥有限公司	胺基六員環類衍生物及其在醫藥上的應用
TWI640524B (zh) *	2015-08-27	2018-11-11	四川海思科製藥有限公司	Aminopyran ring derivatives and compositions and uses thereof
CN105198847B (zh) *	2015-10-28	2017-05-17	四川凯科医药科技有限公司	一种化合物的制备方法
WO2017093209A1 (en) *	2015-12-03	2017-06-08	F.I.S. - Fabbrica Italiana Sintetici S.P.A.	Process for preparing aminotetrahydropyrans
CN105399744B (zh) *	2015-12-17	2017-07-18	黄燕鸽	一种奥格列汀的合成方法
EP3181565A1 (en)	2015-12-18	2017-06-21	Sandoz Ag	Crystalline omarigliptin salts
US10221185B2 (en) *	2015-12-25	2019-03-05	Sichuan Haisco Pharmaceutical Co., Ltd.	Crystal form of substituted aminopyran derivativek
CN106916158A (zh) *	2015-12-25	2017-07-04	四川海思科制药有限公司	一种吡喃衍生物盐酸盐水合物及其中间体的制备方法
CN106928228B (zh) *	2015-12-29	2019-08-30	杭州普晒医药科技有限公司	奥格列汀盐及其晶型、它们的制备方法和药物组合物
CN107337674B (zh) *	2016-04-29	2019-09-20	江苏吉贝尔药业股份有限公司	用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
CN108699068B (zh) *	2016-05-25	2021-01-08	四川海思科制药有限公司	一种三氟甲基取代的吡喃衍生物制备方法
CN109071551B (zh) *	2016-05-25	2020-12-08	四川海思科制药有限公司	一种三氟甲基取代的吡喃衍生物的制备方法
CN107652291B (zh) *	2016-07-26	2020-07-14	中国科学院上海药物研究所	一种制备手性四氢吡喃衍生物的方法
US10822319B2 (en)	2016-08-12	2020-11-03	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Crystal of DPP-IV long-acting inhibitor and salt
CN106674227B (zh) *	2016-12-06	2019-03-19	上海博志研新药物技术有限公司	一种奥格列汀及其中间体的制备方法
EP3335701A1 (en)	2016-12-16	2018-06-20	Hexal AG	Pharmaceutical composition comprising omarigliptin
EP3335702A1 (en)	2016-12-16	2018-06-20	Hexal AG	Pharmaceutical compositions comprising omarigliptin
EP3335704A1 (en)	2016-12-16	2018-06-20	Hexal AG	Pharmaceutical composition comprising omarigliptin
EP3335703A1 (en)	2016-12-16	2018-06-20	Hexal AG	Pharmaceutical composition comprising omarigliptin
CN107024590A (zh) *	2017-03-13	2017-08-08	新疆医科大学	一种诊断1型和2型糖尿病的血清蛋白标志物组
WO2018167589A1 (en)	2017-03-16	2018-09-20	Inventia Healthcare Private Limited	Pharmaceutical composition comprising dapagliflozin
PL3448859T3 (pl)	2017-03-20	2020-02-28	Forma Therapeutics, Inc.	Kompozycje pirolopirolu jako aktywatory kinazy pirogronianowej (PKR)
CN109796455B (zh) *	2017-11-17	2021-02-26	四川海思科制药有限公司	一种氨基吡喃衍生物的盐、其晶型及其制备方法和用途
JP7150862B2 (ja) *	2018-02-06	2022-10-11	スーチュアンハイスークファーマシューティカルカンパニーリミテッド	アミノピラン誘導体の組成物
JP7450610B2 (ja)	2018-09-19	2024-03-15	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	ピルビン酸キナーゼｒの活性化
US20200129485A1 (en)	2018-09-19	2020-04-30	Forma Therapeutics, Inc.	Treating sickle cell disease with a pyruvate kinase r activating compound
CA3145678C (en) *	2019-07-26	2022-08-23	Medshine Discovery Inc.	Sglt2/dpp4 inhibitor and application thereof
CN110568100B (zh) *	2019-09-12	2022-05-31	江西金水宝制药有限公司	一种米格列奈钙r-异构体的检测方法
CN111793071B (zh) *	2020-07-06	2021-06-04	四川凯科医药科技有限公司	奥格列汀的合成工艺

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US5232929A (en)	1990-11-28	1993-08-03	Pfizer Inc.	3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
AU6452098A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
PT970095E (pt)	1997-03-07	2004-03-31	Metabasis Therapeutics Inc	Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
AU6691798A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6613942B1 (en)	1997-07-01	2003-09-02	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
WO1999001423A1 (en)	1997-07-01	1999-01-14	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
AU770319C (en)	1998-05-04	2004-11-25	Point Therapeutics, Inc.	Hematopoietic stimulation
JP2002524463A (ja)	1998-09-09	2002-08-06	メタバシス・セラピューティクス・インコーポレイテッド	フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB9906715D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
ES2250128T3 (es)	1999-05-17	2006-04-16	Novo Nordisk A/S	Antagonistas/agonistas inversos de glucagon.
AU2001277056B2 (en)	2000-07-25	2005-09-29	Merck & Co., Inc.	N-substituted indoles useful in the treatment of diabetes
WO2002034243A2 (en)	2000-10-27	2002-05-02	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders
EP1357908A4 (en)	2001-01-30	2009-07-15	Merck & Co Inc	ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
ES2291477T3 (es)	2001-06-27	2008-03-01	Smithkline Beecham Corporation	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AR040241A1 (es)	2002-06-10	2005-03-23	Merck & Co Inc	Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
NZ538031A (en)	2002-08-29	2007-10-26	Merck & Co Inc	Indoles having anti-diabetic activity
WO2004019869A2 (en)	2002-08-29	2004-03-11	Merck & Co., Inc.	Indoles having anti-diabetic activity
WO2004037159A2 (en)	2002-10-23	2004-05-06	Obetherapy Biotechnology	Compounds, compositions and methods for modulating fat metabolism
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
JO2397B1 (en)	2002-12-20	2007-06-17	ميرك شارب اند دوم كوربوريشن	Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004066963A2 (en)	2003-01-17	2004-08-12	Merck & Co., Inc.	N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
WO2004091499A2 (en)	2003-04-09	2004-10-28	Neose Technologies, Inc.	Intracellular formation of peptide conjugates
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en)	2003-04-23	2004-10-28	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US20050065144A1 (en)	2003-09-08	2005-03-24	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
MXPA06007194A (es)	2003-12-23	2007-01-19	Progen Ind Ltd	Imitaciones de glicosaminoglican (gag).
WO2006009886A1 (en)	2004-06-21	2006-01-26	Merck & Co., Inc.	Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006020372A2 (en)	2004-07-23	2006-02-23	Neose Technologies, Inc.	Enzymatic modification of glycopeptides
US7718667B2 (en)	2004-09-28	2010-05-18	Merck Sharp & Dohme Corp.	Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006058064A2 (en)	2004-11-29	2006-06-01	Merck & Co., Inc.	Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2582447C (en)	2004-10-01	2012-04-17	Merck & Co., Inc.	Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2005299808B2 (en)	2004-10-25	2009-08-20	Novartis Ag	Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
CN101090888A (zh)	2004-12-20	2007-12-19	霍夫曼-拉罗奇有限公司	4－氨基哌啶衍生物
US7411093B2 (en)	2004-12-20	2008-08-12	Hoffman-La Roche Inc.	Aminocycloalkanes as DPP-IV inhibitors
EP1702916A1 (en)	2005-03-18	2006-09-20	Santhera Pharmaceuticals (Schweiz) GmbH	DPP-IV inhibitors
TWI357902B (en) *	2005-04-01	2012-02-11	Lg Life Science Ltd	Dipeptidyl peptidase-iv inhibiting compounds, meth
WO2006127530A2 (en)	2005-05-25	2006-11-30	Merck & Co., Inc.	Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
KR101349808B1 (ko)	2005-06-13	2014-02-13	임페리얼 이노베이션스 리미티드	섭취행동에 관한 신규 화합물들 및 이들의 효능
EP1921917B1 (en)	2005-08-26	2012-03-21	Merck Sharp & Dohme Corp.	Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5075129B2 (ja)	2005-12-14	2012-11-14	メルク・シャープ・エンド・ドーム・コーポレイション	糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−４阻害剤としての縮合アミノピペリジン
CA2636757A1 (en)	2006-01-25	2007-08-02	Tesfaye Biftu	Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5161795B2 (ja)	2006-02-15	2013-03-13	メルク・シャープ・エンド・ドーム・コーポレイション	糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
CN101389648B (zh)	2006-02-22	2013-07-17	默沙东公司	肽胃泌酸调节素衍生物
EP1999143B1 (en)	2006-03-20	2011-07-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
TW200806669A (en) *	2006-03-28	2008-02-01	Merck & Co Inc	Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2007254357B2 (en)	2006-05-16	2011-07-21	Merck Sharp & Dohme Corp.	Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
MX2009000748A (es)	2006-07-18	2009-03-31	Centocor Inc	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
WO2008060488A1 (en) *	2006-11-14	2008-05-22	Merck & Co., Inc.	Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2111414B1 (en)	2007-02-15	2014-07-02	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
EP2170883A1 (en)	2007-06-28	2010-04-07	Merck Frosst Canada Ltd.	Substituted fused pyrimidines as antagonists of gpr105 activity
WO2009011836A1 (en)	2007-07-19	2009-01-22	Merck & Co., Inc.	Beta carboline derivatives as antidiabetic compounds
WO2009014676A1 (en) *	2007-07-23	2009-01-29	Merck & Co., Inc.	Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
AU2008289573B2 (en)	2007-08-21	2013-05-16	Merck Sharp & Dohme Corp.	Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20110301079A1 (en)	2007-09-21	2011-12-08	Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Neuromedin u receptor agonists and uses thereof
US7902376B2 (en)	2008-01-23	2011-03-08	Merck Sharp & Dohme Corp.	Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates
CN102272135A (zh)	2008-10-08	2011-12-07	百时美施贵宝公司	唑并吡咯酮黑色素浓集激素受体-1拮抗剂
JO2870B1 (en) *	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes

2009
- 2009-11-04 JO JO2009408A patent/JO2870B1/en active
- 2009-11-09 AR ARP090104318 patent/AR074306A1/es unknown
- 2009-11-09 TW TW98137972A patent/TWI398443B/zh not_active IP Right Cessation
- 2009-11-11 MY MYPI20112075 patent/MY150787A/en unknown
- 2009-11-11 UA UAA201107305A patent/UA101414C2/uk unknown
- 2009-11-11 BR BRPI0921375A patent/BRPI0921375B8/pt active IP Right Grant
- 2009-11-11 AU AU2009314191A patent/AU2009314191B2/en active Active
- 2009-11-11 CA CA 2742783 patent/CA2742783C/en active Active
- 2009-11-11 PT PT09756204T patent/PT2358717E/pt unknown
- 2009-11-11 WO PCT/US2009/063976 patent/WO2010056708A1/en active Application Filing
- 2009-11-11 EP EP20130180590 patent/EP2676959A1/en not_active Withdrawn
- 2009-11-11 DK DK09756204T patent/DK2358717T3/da active
- 2009-11-11 EA EA201170670A patent/EA018613B1/ru not_active IP Right Cessation
- 2009-11-11 CN CN200980154484.2A patent/CN102272136B/zh active Active
- 2009-11-11 PA PA8848201A patent/PA8848201A1/es unknown
- 2009-11-11 MX MX2011005044A patent/MX2011005044A/es active IP Right Grant
- 2009-11-11 SI SI200930757T patent/SI2358717T1/sl unknown
- 2009-11-11 EP EP13180592.1A patent/EP2676960B1/en active Active
- 2009-11-11 RS RSP20130426 patent/RS52946B/en unknown
- 2009-11-11 JP JP2011536433A patent/JP4854825B1/ja active Active
- 2009-11-11 EP EP20090756204 patent/EP2358717B1/en active Active
- 2009-11-11 EP EP13180593.9A patent/EP2676961B1/en active Active
- 2009-11-11 GE GEAP200912261A patent/GEP20135724B/en unknown
- 2009-11-11 NZ NZ592826A patent/NZ592826A/en not_active IP Right Cessation
- 2009-11-11 KR KR20127021008A patent/KR101454093B1/ko active IP Right Grant
- 2009-11-11 PE PE2011001028A patent/PE20120027A1/es not_active Application Discontinuation
- 2009-11-11 KR KR1020117010775A patent/KR101260162B1/ko active IP Right Grant
- 2009-11-11 PL PL09756204T patent/PL2358717T3/pl unknown
- 2009-11-11 ES ES09756204T patent/ES2432191T3/es active Active
- 2009-11-12 US US12/616,831 patent/US8143289B2/en active Active
2011
- 2011-04-21 TN TN2011000201A patent/TN2011000201A1/fr unknown
- 2011-04-26 IL IL212485A patent/IL212485A/en not_active IP Right Cessation
- 2011-04-28 NI NI201100081A patent/NI201100081A/es unknown
- 2011-05-06 HN HN2011001256A patent/HN2011001256A/es unknown
- 2011-05-09 DO DO2011000128A patent/DOP2011000128A/es unknown
- 2011-05-11 EC ECSP11011044 patent/ECSP11011044A/es unknown
- 2011-05-12 CL CL2011001082A patent/CL2011001082A1/es unknown
- 2011-05-12 CO CO11058568A patent/CO6382129A2/es active IP Right Grant
- 2011-05-12 SV SV2011003903A patent/SV2011003903A/es unknown
- 2011-05-13 CR CR20110257A patent/CR20110257A/es unknown
- 2011-06-08 MA MA33925A patent/MA32887B1/fr unknown
- 2011-07-06 JP JP2011150098A patent/JP5537507B2/ja active Active
- 2011-08-25 HK HK11108978A patent/HK1154849A1/xx not_active IP Right Cessation
2012
- 2012-02-17 US US13/398,887 patent/US8415297B2/en active Active
2013
- 2013-02-07 US US13/761,407 patent/US8592371B2/en active Active
- 2013-03-13 IL IL225198A patent/IL225198A/en active IP Right Grant
- 2013-10-01 HR HRP20130924AT patent/HRP20130924T1/hr unknown
- 2013-10-22 US US14/059,638 patent/US8772328B2/en active Active
- 2013-10-31 CY CY20131100966T patent/CY1114617T1/el unknown
2014
- 2014-06-02 US US14/293,031 patent/US8951965B2/en active Active
2015
- 2015-01-07 US US14/591,124 patent/US9138426B2/en active Active
- 2015-08-13 US US14/825,535 patent/US9278976B2/en active Active
2016
- 2016-01-26 US US15/006,220 patent/US9403790B2/en active Active

Also Published As

Publication number	Publication date
EP2358717A1 (en)	2011-08-24
RS52946B (en)	2014-02-28
AU2009314191A1 (en)	2010-05-20
US20150126443A1 (en)	2015-05-07
US9138426B2 (en)	2015-09-22
US8143289B2 (en)	2012-03-27
KR101260162B1 (ko)	2013-05-09
PT2358717E (pt)	2013-11-26
US20130157940A1 (en)	2013-06-20
BRPI0921375B8 (pt)	2021-05-25
CO6382129A2 (es)	2012-02-15
SV2011003903A (es)	2011-10-13
EP2676961A1 (en)	2013-12-25
UA101414C2 (uk)	2013-03-25
US8951965B2 (en)	2015-02-10
HK1154849A1 (en)	2012-05-04
EP2676960B1 (en)	2017-04-19
US8415297B2 (en)	2013-04-09
US8772328B2 (en)	2014-07-08
CY1114617T1 (el)	2016-10-05
EA018613B1 (ru)	2013-09-30
US20120149637A1 (en)	2012-06-14
MY150787A (en)	2014-02-28
CL2011001082A1 (es)	2012-02-24
IL212485A (en)	2013-08-29
US20150344487A1 (en)	2015-12-03
IL212485A0 (en)	2011-06-30
PA8848201A1 (es)	2010-06-28
HN2011001256A (es)	2013-10-14
US20140051740A1 (en)	2014-02-20
PL2358717T3 (pl)	2014-01-31
US20160137622A1 (en)	2016-05-19
BRPI0921375B1 (pt)	2020-11-03
NI201100081A (es)	2011-11-03
JP2011251973A (ja)	2011-12-15
DK2358717T3 (da)	2013-11-18
KR101454093B1 (ko)	2014-10-27
ECSP11011044A (es)	2011-06-30
EA201170670A1 (ru)	2011-12-30
US9278976B2 (en)	2016-03-08
IL225198A (en)	2016-02-29
MA32887B1 (fr)	2011-12-01
JP5537507B2 (ja)	2014-07-02
US8592371B2 (en)	2013-11-26
CN102272136A (zh)	2011-12-07
CA2742783C (en)	2013-01-08
EP2676961B1 (en)	2017-04-19
TW201024299A (en)	2010-07-01
EP2676959A1 (en)	2013-12-25
HRP20130924T1 (hr)	2013-11-08
AR074306A1 (es)	2011-01-05
CA2742783A1 (en)	2010-05-20
TN2011000201A1 (en)	2012-12-17
NZ592826A (en)	2012-06-29
MX2011005044A (es)	2011-06-17
US20100120863A1 (en)	2010-05-13
JO2870B1 (en)	2015-03-15
AU2009314191B2 (en)	2012-02-16
WO2010056708A1 (en)	2010-05-20
BRPI0921375A2 (pt)	2015-12-29
CR20110257A (es)	2011-07-01
US20140287993A1 (en)	2014-09-25
KR20110074581A (ko)	2011-06-30
TWI398443B (zh)	2013-06-11
JP2012508746A (ja)	2012-04-12
EP2358717B1 (en)	2013-08-21
GEP20135724B (en)	2013-01-10
EP2676960A1 (en)	2013-12-25
CN102272136B (zh)	2015-01-14
JP4854825B1 (ja)	2012-01-18
US9403790B2 (en)	2016-08-02
KR20120107133A (ko)	2012-09-28
DOP2011000128A (es)	2011-06-30
PE20120027A1 (es)	2012-02-05
ES2432191T3 (es)	2013-12-02

Publication	Publication Date	Title
IL212485A0 (en)	2011-06-30	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1986652A4 (en)	2012-02-22	AMINOETETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1978804A4 (en)	2013-02-20	AMINOCYCLOHEXANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR TREATING OR PREVENTING DIABETES
EP2019677A4 (en)	2011-09-21	AMINOETETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP2473047A4 (en)	2013-02-13	AMINOETETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP2190428A4 (en)	2012-02-29	HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
ZA200807488B (en)	2009-11-25	Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2480082A4 (en)	2014-01-15	SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
EP2094081A4 (en)	2011-01-05	TRICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1761532A4 (en)	2009-05-27	AMINOCYCLOHEXANES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
HUS1700051I1 (hu)	2017-12-28	Pirrolopiridin vegyületek, mint CDK inhibitorok
EP1962601A4 (en)	2010-10-27	Fused Amino Coperidines As Diphosphatipetidase 4 Inhibitors For Treating Or Preventing Diabetes
EP2538783A4 (en)	2013-08-07	SUBSTITUTED AMINOTETRAHYDROTHIOPYRANEES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
HK1148435A1 (en)	2011-09-09	Oxadiazoanthracene compounds for the treatment of diabetes
PL2247602T3 (pl)	2013-08-30	Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy
EP1756106A4 (en)	2008-12-17	CYCLOHEXYLALANINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
ZA200902374B (en)	2009-12-30	Compositions useful for the treatment of diabetes
IL230683A0 (en)	2014-03-31	dpp-iv inhibitors for use in the treatment of nafld
IL190131A0 (en)	2008-11-03	Dipeptidyl peptidase inhibitors for treating diabetes
IL190133A0 (en)	2008-11-03	Dipeptidyl peptidase inhibitors for treating diabetes
ZA200704154B (en)	2008-09-25	Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
ZA201006827B (en)	2011-05-25	Carboxamide-heteroaryl derivatives for the treatment of diabetes
HK1169993A1 (en)	2013-02-15	Hsl inhibitors useful in the treatment of diabetes hsl
IL211189A0 (en)	2011-04-28	Compounds for the treatment of peripheral neuropathies
EP2358200A4 (en)	2012-05-16	BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES